ONO Enters into License Agreement with Bristol-Myers Squibb for Prostaglandin E2 Receptor Antagonists relating to Immuno-Oncology Programs (44.1KB)
(WorldNews Asia)

December 14, 2017 ONO Enters into License Agreement with Bristol-Myers Squibb for Prostaglandin E2 Receptor Antagonists relating to Immuno-Oncology Programs ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President, Representative Director, Gyo Sagara; "ONO") announced that ONO entered into a license agreement with Bristol-Myers Squibb Company (NYSE: BMY; "BMS") for the development and commercialization of ONO-4578, a selective antagonist of EP4 which is a Prostaglandin E2 (PGE2) receptor. This agreement also includes the collaboration to discover and develop other compounds from PGE2 receptor antagonist programs. Under the terms of this agreement, BMS is granted the rights...